Canlyniadau Chwilio - Jaume Capdevila

Mireinio'r Canlyniadau
  1. 1
    Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib

    Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib gan Jaume Capdevila, Neda Stjepanovic

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    GEP–NETs UPDATE: Biotherapy for neuroendocrine tumours

    GEP–NETs UPDATE: Biotherapy for neuroendocrine tumours gan Teresa Alonso‐Gordoa, Jaume Capdevila, Enrique Grande

    Cyhoeddwyd 2014
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies

    Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies gan Enrique Grande, Juan J. Díez, Carles Zafón, Jaume Capdevila

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer

    Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer gan Anubha Gupta, Barbara Jarząb, Jaume Capdevila, Robert Shumaker, Ziad Hussein

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    What is the status of immunotherapy in thyroid neoplasms?

    What is the status of immunotherapy in thyroid neoplasms? gan Alejandro García‐Álvarez, Jorge Hernando, Ana Carmona-Alonso, Jaume Capdevila

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era

    Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era gan Jaume Capdevila, Ahmad Awada, Dagmar Führer‐Sakel, Sophie Leboulleux, Patrick Pauwels

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia

    Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia gan Rodrigo A. Toledo, Camilo Jiménez, Gustavo Armaiz-Peña, Carlota Arenillas, Jaume Capdevila, Patricia L. M. Dahia

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Cabozantinib for the treatment of solid tumors: a systematic review

    Cabozantinib for the treatment of solid tumors: a systematic review gan Pablo Maroto, Camillo Porta, Jaume Capdevila, Andrea B. Apolo, Santiago Viteri, Cristina Rodríguez‐Antona, Lidia Martín, Daniel Castellano

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Genomics Review of Selective <scp>RET</scp> Inhibitors Sensitivity in Thyroid Cancer Clinical Trials

    Genomics Review of Selective <scp>RET</scp> Inhibitors Sensitivity in Thyroid Cancer Clinical Trials gan Sara Gil‐Bernabé, Lucía García‐DeLaFuente, Alejandro García‐Álvarez, Ginesa García‐Rostán, Jaume Capdevila, Jorge Hernando

    Cyhoeddwyd 2025
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Streptozotocin, 1982–2022: Forty Years from the FDA’s Approval to Treat Pancreatic Neuroendocrine Tumors

    Streptozotocin, 1982–2022: Forty Years from the FDA’s Approval to Treat Pancreatic Neuroendocrine Tumors gan Jaume Capdevila, Michel Ducreux, Rocio García‐Carbonero, Enrique Grande, Þorvarður R. Hálfdánarson, Anne Couvelard, Salvatore Tafuto, Staffan Welin, Vicente Valentí, Ramón Salazar

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies

    Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies gan Enrique Grande, Michael C. Kreißl, Sébastiano Filetti, Kate Newbold, Walter Reinisch, Caroline Robert, Martin Schlumberger, Lærke Kjær Tolstrup, José Luís Zamorano, Jaume Capdevila

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development

    Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in dev... gan Rocio García‐Carbonero, Roberto García‐Figueiras, Alberto Carmona‐Bayonas, Isabel Sevilla, Àlex Teulé, María Quindós, Enrique Grande, Jaume Capdevila, Javier Aller, Javier Arbizu, Paula Jiménez‐Fonseca

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Sorafenib in metastatic thyroid cancer

    Sorafenib in metastatic thyroid cancer gan Jaume Capdevila, L. Iglesias, Irene Halperín, Ángel Segura, Javier Martínez‐Trufero, María Ángeles Vaz Salgado, J. Corral, Gabriel Obiols, Enrique Grande, Juan J. Grau, Josep Tabernero

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

    Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors gan Catherine Lombard‐Bohas, James C. Yao, Timothy J. Hobday, Eric Van Cutsem, Edward M. Wolin, Ashok Panneerselvam, Sotirios Stergiopoulos, Manisha H. Shah, Jaume Capdevila, Rodney F. Pommier

    Cyhoeddwyd 2014
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results

    Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results gan Marianne Pavel, Jarosław B. Ćwikła, Catherine Lombard‐Bohas, Ivan Borbath, Tahir Shah, Ulrich F. Pape, Jaume Capdevila, Francesco Panzuto, Xuan-Mai Truong Thanh, Aude Houchard, Philippe Ruszniewski

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer

    Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer gan Bruce Robinson, Martin Schlumberger, Lori J. Wirth, Corina E. Dutcus, James Song, Matthew H. Taylor, Sung‐Bae Kim, Monika K. Krzyzanowska, Jaume Capdevila, Steven I. Sherman, Makoto Tahara

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve <i>RET</i> -Mutant Medullary Thyroid Cancer

    Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve <i>RET</i> -Mutant Medullary Thyroid Cancer gan Lori J. Wirth, Marcia S. Brose, Rossella Elisei, Jaume Capdevila, Ana O. Hoff, Mimi I. Hu, Makoto Tahara, Bruce Robinson, Ming Gao, Xia Meng, Patricia Maeda, Eric J. Sherman

    Cyhoeddwyd 2022
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

    ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors gan Massimo Falconi, Barbro Eriksson, Gregory Kaltsas, Detlef K. Bartsch, Jaume Capdevila, Martyn Caplin, Beata Kos‐Kudła, Dik J. Kwekkeboom, Guido Rindi, Günter Klöppel, Nicholas S. Reed, Réza Kianmanesh, Robert T. Jensen

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer

    Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer gan Garazi Serna, Fiorella Ruíz‐Pace, Jorge Hernando, Lidia Alonso, Roberta Fasani, Stefania Landolfi, Raquel Comas, José Jiménez, Elena Élez, Susan Bullman, Josep Tabernero, Jaume Capdevila, Rodrigo Dienstmann, Paolo Nucíforo

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

    A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors gan Josep Tabernero, Luc Dirix, Patrick Schöffski, Andrés Cervantes, José A. López-Martín, Jaume Capdevila, Ludy van Beijsterveldt, Suso Platero, Brett M. Hall, Zhilong Yuan, R.E. Knoblauch, Sen Hong Zhuang

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: